Taipei Times
Date: Jul 30, 2019
By: Kao Shih-ching  /  Staff reporter

TaiMed Biologics Inc (中裕新藥) yesterday said that it plans to market its Trogarzo HIV treatment in Germany by the end of this year, expressing confidence that it would obtain marketing approval from European regulators in October.

The European Medicines Agency’s (EMA) human medicines committee had a positive opinion on Trogarzo at a meeting on Friday last week, TaiMed chief financial officer Jack Chen (陳怡成) said.

That is important for TaiMed’s business in Europe, as the European Commission takes the committee’s recommendation into account when deciding on marketing approval for new treatments, Chen said.

“If everything goes smoothly, it is likely that we will receive marketing approval in early October,” Chen said.

TaiMed and its business partner, Canada-based Theratechnologies Inc, have decided that Germany would be Trogarzo’s first European market, he said.    [FULL  STORY]